Sign in
Taking people in United StatesNo phase

Effects of pausing nerve stimulation therapy on heart and metabolism in sleep apnea

Tests how stopping nerve stimulation briefly affects heart and metabolism measures in obstructive sleep apnea.

Key facts

Who runs it
Columbia University
Where
New York, United StatesSee the site
Trial code
Registry title
Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy
Status
Recruiting
People taking part
60 people, planned
Started
5 Jan 2025
Expected to end
Jan 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • No HGNS therapy (HGNS-off)
Record updated
10 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for English-speaking adults with obstructive sleep apnea who already use an implanted hypoglossal nerve stimulation (HGNS) device that works well for them. The study looks at heart and metabolism measures when HGNS is turned off for a short time.

Age
18 years and older
Sex
All sexes
Disease stage
Obstructive sleep apnea that improved with HGNS: at least a 50% drop in apnea-hypopnea index (AHI, breathing pauses per hour) to <20.
Earlier treatment
Must have used HGNS for at least 3 months, and for >20 hours/week in the past 4 weeks. Must have had no sleep apnea treatment for at least one month before HGNS was switched on, or a one-month untreated period after.

Main reasons for not taking part

  • Long-term use of opiate medicines, illegal drugs, or alcohol dependency
  • Pregnant or planning to become pregnant
  • Shift workers, heavy machinery operators, or commercial drivers
  • Severe daytime sleepiness (Epworth score >16), or car accidents or near misses from drowsy driving in the past year
  • Serious heart, lung, liver, kidney, cancer or brain-degenerating disease, or an eating disorder in the last 5 years

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • English-speaking adults (18+ years) who have met surgical efficacy criteria with HGNS, as defined by at least a 50% reduction in apnea-hypopnea index (AHI) to <20 (with hypopneas defined by 4% oxyhemoglobin desaturations)
  • Have been using HGNS therapy for at least 3 months and used HGNS for >20 hours/week during the past 4 weeks
  • Were not using any OSA therapy for at least one month prior to HGNS activation or have had a one-month period of untreated OSA after HGNS activation

Who cannot take part

  • Chronic use of opiate medications, illicit drugs, or alcohol dependency
  • History of severe excessive daytime sleepiness (Epworth Sleepiness Scale score >16 at time of screening or prior to HGNS), motor vehicle accidents or near-miss incidents due to drowsy driving within the year prior to enrollment
  • Significant cardiopulmonary (such as home oxygen requirement), liver, renal, or oncologic disease; neurodegenerative disease; active or recent history of an eating disorder (within the last 5 years)
  • Women who are pregnant or planning to become pregnant
  • Shift workers, heavy machinery operators, or commercial drivers
  • Inability to provide informed consent

Where in United States

  • Columbia University Medical CenterNew York, United StatesContact: Jesus LopezTaking people

About the trial

What the trial wants to find out

Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea.

Read full original descriptionShow less

The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).

The 2 groups in the trial

  • Therapeutic HGNS (HGNS-on)No study treatment, for comparison

    Prior to enrollment in this study, participants will have been implanted with and stabilized on HGNS therapy. As part of clinical care, a therapeutic voltage setting will have been confirmed via overnight sleep study. This arm of the study maintains the participants on the HGNS therapy at the therapeutic voltage they have been using. This is a representation of the patient's baseline status.

  • No HGNS therapy (HGNS-off)Other group

    HGNS therapy will be turned off by the participant for this arm of the study. This arm will mimic the participant's untreated OSA statement before they had HGNS therapy activated.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cardiometabolic Risk Effects of Short-term Cessation of Effective Neurostimulation Therapy in OSA
Plain-language title
Effects of pausing nerve stimulation therapy on heart and metabolism in sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
10 July 2025